19 hrs ago
$1,000 Sovaldi now hepatitis treatment of choice
The price is sky-high, but so is demand. A new $1,000-per-pill drug has become the treatment of choice for Americans with hepatitis C, a liver-wasting disease that affects more than 3 million.
Thu Jul 31, 2014
Contribution of the organic anion transporter OAT2 to the renal...
Correspondence: Adrian S. Ray, Gilead Sciences, 333 Lakeside Drive, Foster City, California 94404, USA.
3 Biotech Catalyst Stocks To Own
For companies involved in the research of drugs, no catalyst is able to trump coming out with clinical trial results.
Illinois Medicaid restricts use of hepatitis drug
This handout photo provided by Gilead Sciences shows the hepatitis C medication Sovaldi.
Wed Jul 30, 2014
Gilead's Massive Undervaluation: A Pictorial Overview
Despite the rally in the stock the shares are still extremely cheap compared to other large cap biotech concerns as well as against other large cap growth plays.
Gilead Sciences, Inc. Allows China/Indian Pharmas To Make Generic Version Of Novel HIV Drug
July 29, 2014 -- Gilead Sciences will allow China and Indian drugmakers to start developing generic formulations of a promising novel HIV/HBV drug, even though the drug's Phase III tests are still underway.
Gilead Sciences Popular Amongst Latest 13F Filers
At Holdings Channel , we have reviewed the latest batch of the 23 most recent 13-F filings for the 06/30/2014 reporting period, and noticed that Gilead Sciences, Inc. was held by 13 of these funds.
Theraclone Sciences cuts HIV antibodies deal with Gilead
Theraclone Sciences Inc. of Seattle said it's made a deal with Gilead Sciences Inc. that will allow the Foster City-based biotech giant to develop and commercialize Theraclone's neutralizing HIV-antibodies for therapeutic applications in HIV.
Tue Jul 29, 2014
$1,000 pill now hepatitis C treatment of choice
In less than six months, prescriptions for Sovaldi have eclipsed all other hepatitis C pills combined, according to new data from IMS Health.
Mon Jul 28, 2014
In Europe, two drugs will compete to treat rare blood cancer
In Europe, two Bay Area pharmaceutical companies will go head-to-head over new drugs that both treat a rare blood cancer, chronic lymphocytic leukemia, in patients whose disease has returned.
Diplomat receives distribution contract for ZydeligA
Diplomat, the nation's largest independent specialty pharmacy, announced today that it has been selected as a provider of Zydelig tablets.
Why Gilead Sciences (GILD) Stock Is Up Today
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.
Why Gilead Sciences (GILD) Stock Is Up Today
The company's new price target represents 41% upside from its opening price today.
Sat Jul 26, 2014
The Motley Fool
This Week in Biotech: Puma Sprints, Gilead Sweeps, and Inovio Hits the Mark
With the SPDR S&P Biotech Index up 22% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector.
Fri Jul 25, 2014
Gilead Sciences, Inc. v. Natco Pharma Ltd.
Case Name: Gilead Sciences, Inc. v. Natco Pharma Ltd. , 2013-1418, 2014 U.S. App.
Science and Society: Let's Fight HIV and Hep C Together
Scientists and community members have striven to make their points and find common ground on this last full day of the XX International AIDS Conference on Thursday.
Investor's Business Daily
European CHMP Adopts Positive Opinion for Gilead's Zydelig ...
Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use , the scientific committee of the European Medicines Agency , has adopted a positive opinion on the company's Marketing Authorization Application for ZydeligA , a first-in-class treatment for patients with chronic lymphocytic leukemia and follicular ... (more)
$1,000-a-pill hepatitis C drug boosts Gilead's fortunes
Sales of the new hepatitis C drug Sovaldi reached $3.5 billion in the second quarter, putting it on track to become one of the world's best-selling medicines and intensifying concerns about its costs.
Thu Jul 24, 2014
Gilead hepatitis C pill reaches $3.48 billion in quarterly sales
Despite criticism from insurers and lawmakers, Gilead Sciences said Wednesday its $1,000-a-day hepatitis C pill had improved on its record-setting debut as it reached $3.48 billion in sales last quarter.
Sovaldi Debate Continues: Will Medicaid And Insurance Companies...
Since gaining approval from the Food and Drug Administration in December, Sovaldi, the hepatitis C drug, has courted controversy due to its steep $1,000-a-pill price.